Journal of Neural Transmission

, Volume 116, Issue 4, pp 457–465 | Cite as

Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer’s disease: an updated meta-analysis

  • Bai-song Wang
  • Hao Wang
  • Zhao-hui Wei
  • Yan-yan Song
  • Lu Zhang
  • Hong-zhuan Chen
Dementias - Original Article

Abstract

The objective of this study was to provide an updated meta-analysis of the efficacy and safety of huperzine A (HupA) in Alzheimer’s disease (AD). We searched for randomized trials comparing HupA with placebo in the treatment of AD. The primary outcome measures were mini-mental state examination (MMSE) and activities of daily living scale (ADL). Data were extracted from four randomized clinical trials and analyzed using standard meta-analysis and meta-regression methods. Oral administration of HupA for 8–24 weeks (300–500 μg daily) led to significant improvements in MMSE and ADL. The results of meta-regression showed that the estimated effect size of MMSE and ADL was increased over the treatment time. Most adverse events were cholinergic in nature and no serious adverse events occurred. Huperzine A is a well-tolerated drug that could significantly improve cognitive performance and ADL in patients with AD.

Keywords

Alzheimer’s disease Huperzine A Acetylcholinesterase inhibitor Clinical trials Meta-analysis Meta-regression 

References

  1. Bai DL, Tang XC, He XC (2000) Huperzine A, a potential therapeutic agent for treatment of Alzheimer’s disease. Curr Med Chem 7:355–374PubMedGoogle Scholar
  2. Chen MJ, Gao ZX, Deng HY, Liu FG (2000) A multi-center, double-blind clinical trial of huperzine-A in capsules and tablets for treating patients with Alzheimer disease. Chin J New Drugs Clin Rem 19:10–12Google Scholar
  3. Dong HT, Jin YG, Bai Y (2002) 11 cases of Alzheimer’s disease treated by acupuncture. Acta Universitatis Traditionis Medicalis Sinensis Pharmacologiaeque Shanghai 16:26–28Google Scholar
  4. Follmann D, Elliott P, Suh I, Cutler J (1992) Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 45:769–773PubMedCrossRefGoogle Scholar
  5. Folstein M, Folstein S, McHugh P (1975) The mini-mental state examination. J Psychiatr Res 12:189–198PubMedCrossRefGoogle Scholar
  6. Giacobini E (2004) Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol Res 50:433–440PubMedCrossRefGoogle Scholar
  7. Isaac MG, Quinn R, Tabet N (2008) Vitamin E for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev (3). Art. No.: CD002854. doi: 10.1002/14651858.CD002854
  8. Kelley BJ, Knopman DS (2008) Alternative medicine and Alzheimer disease. Neurologist 14:299–306PubMedCrossRefGoogle Scholar
  9. Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9:179–186PubMedGoogle Scholar
  10. Li J, Wu HM, Zhou RL, Liu GJ, Dong BR (2008) Huperzine A for Alzheimer’s disease. Cochrane Database Syst Rev (2). Art. No.: CD005592. doi:10.1002/14651858.CD005592
  11. Little JT, Walsh S, Aisen PS (2008) An update on huperzine A as a treatment for Alzheimer’s disease. Expert Opin Investig Drugs 17:209–215PubMedCrossRefGoogle Scholar
  12. Liu FG, Fang YS, Gao ZX, Zhou JD, Su ML (1995) Double-blind control treatment of huperzine-A and placebo in 28 patients with Alzheimer disease. Chin J Pharmacoepidemiol 4:196–197Google Scholar
  13. Ma X, Tan C, Zhu D, Gang DR, Xiao P (2007) Huperzine A from Huperzia species—an ethnopharmacolgical review. J Ethnopharmacol 113:15–34PubMedCrossRefGoogle Scholar
  14. Mazurek A (2000) An open-label trial of huperzine A in the treatment of Alzheimer’s disease. Altern Ther Health Med 5:97–98Google Scholar
  15. Normand SLT (1999) Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med 18:321–359PubMedCrossRefGoogle Scholar
  16. Rogers SL, Doody RS, Hohs RC, Friedhoff LT, Donepezil Study Group (1998a) Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind placebo-controlled study. Arch Intern Med 158:1021–1031PubMedCrossRefGoogle Scholar
  17. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT (1998b) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 50:136–145PubMedGoogle Scholar
  18. Schneider LS (2001) Assessing outcomes in Alzheimer disease. Alzheimer Dis Assoc Disord 15:S8–S18PubMedCrossRefGoogle Scholar
  19. Tang XC, De Sarno P, Sugaya K, Giacobini E (1989) Effect of huperzine A, a new cholinesterase inhibitor, on the central cholinergic system of the rat. J Neurosci Res 24:276–285PubMedCrossRefGoogle Scholar
  20. Thompson SG, Higgins JP (2002) How should meta-regression analyses be undertaken and interpreted? Stat Med 21:1559–1573PubMedCrossRefGoogle Scholar
  21. Van Houwelingen HC, Arends LR, Stijnen T (2002) Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 21:589–624PubMedCrossRefGoogle Scholar
  22. Ved HS, Koenig ML, Dave JR, Doctor BP (1997) Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate. Neuroreport 8:963–968PubMedCrossRefGoogle Scholar
  23. Wang R, Yan H, Tang XC (2006) Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin 27:1–26PubMedCrossRefGoogle Scholar
  24. Whitehead A (2002) Meta-analysis of controlled clinical trial. Wiley, ChichesterCrossRefGoogle Scholar
  25. Wong DM, Greenblatt HM, Dvir H, Carlier PR, Han YF, Pang YP, Silman I, Sussman JL (2003) Acetylcholinesterase complexed with bivalent ligands related to huperzine a: experimental evidence for species-dependent protein-ligand complementarity. J Am Chem Soc 125:363–373PubMedCrossRefGoogle Scholar
  26. Xu SS, Gao ZX, Weng Z, Du ZM, Xu WA, Yang JS, Zhang ML, Tong ZH, Fang YS, Chai XS, Li SL (1995) Efficacy of tablet huperzine A on memory, cognition, and behavior in Alzheimer’s disease. Acta Pharmacol Sin 16:391–395Google Scholar
  27. Xu SS, Cai ZY, Qu ZW, Yang RM, Cai YL, Wang GQ, Su XQ, Zhong XS, Cheng RY, Xu WA, Li JX, Feng B (1999) Huperzine-A in capsules and tablets for treating patients with Alzheimer disease. Acta Pharmacol Sin 20:486–490Google Scholar
  28. Yan H, Tang XC (2006) Review on clinical application of huperzine A in China. Chin J New Drugs Clin Rem 25:682–687Google Scholar
  29. Yang JS, Jiang ZH (1996) The clinical report of the effect of huperzine A in treatment of Alzheimer’s disease. Heibei Jing Shen Wei Sheng 9:84–85Google Scholar
  30. Yang CY, Lu ZP, Zheng CG (2003) Efficacy and reliability of huperzine A in mild and moderate Alzheimer’s disease. Chin J Clin Rehabil 7:4258–4259Google Scholar
  31. Zhang HY, Tang XC (2006) Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. Trends Pharmacol Sci 27:619–625PubMedCrossRefGoogle Scholar
  32. Zhang ZX, Wang XD, Chen QT, Shu L, Wang JZ, Shan GL (2002) Clinical efficacy and safety of huperzine A in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial. Zhonghua Yi Xue Za Zhi 82:941–944PubMedGoogle Scholar
  33. Zhang ML, Yuan GZ, Yao JJ, Bi P, Ni SQ (2006) Evaluation of clinical effect and safety of huperzine A in treating 52 Alzheimer’s disease. Chin J New Drugs Clin Rem 25:693–695Google Scholar
  34. Zhang HY, Zheng CY, Yan H, Wang ZF, Tang LL, Gao X, Tang XC (2008) Potential therapeutic targets of huperzine A for Alzheimer’s disease and vascular dementia. Chem Biol Interact 175:396–402PubMedCrossRefGoogle Scholar
  35. Zhou BR, Xu ZQ, Kuang YF, Deng YH (2004) Curative effect of aspirin for postponing the development of Alzheimer’s disease. Chin J Clin Rehabil 8:3020–3021Google Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Bai-song Wang
    • 1
  • Hao Wang
    • 1
  • Zhao-hui Wei
    • 1
  • Yan-yan Song
    • 1
  • Lu Zhang
    • 2
  • Hong-zhuan Chen
    • 1
  1. 1.Department of Pharmacology and Biostatistics, Institute of Medical SciencesShanghai Jiaotong University School of MedicineShanghaiChina
  2. 2.Department of Biomedical Engineering, Institute of Medical SciencesShanghai Jiaotong University School of MedicineShanghaiChina

Personalised recommendations